On behalf of the Community Oncology Alliance (COA), Ted Okon, executive director of COA, has released a statement regarding the Prescription Drug Pricing Reduction Act.
On behalf of the Community Oncology Alliance (COA), Ted Okon, executive director of COA, has released a statement regarding the Prescription Drug Pricing Reduction Act. While COA supports certain provisions in the package, including encouraging a healthy and competitive biosimilars market, transparency around pharmacy benefit managers, and changes to grandfathered site-neutral payments for hospitals, there are some provisions COA is opposed to. For example: the proposal to include support from patient assistance programs in the calculation of Average Sales Price, which is the basis for Medicare Part B drug reimbursement.
According to Okon, the provision would lead to drug manufacturers to reduce or eliminate programs. Read the full press release.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Contributor: The Diabetes Vendor Resource Guide—A Useful Directory for Employers
November 13th 2024Employees living with diabetes often face unique challenges, such as managing blood sugar levels, balancing medication, and preventing complications, all while maintaining their professional responsibilities. This condition can lead to increased absenteeism, reduced productivity, and rising health care costs.
Read More